<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01146821</url>
  </required_header>
  <id_info>
    <org_study_id>FK-FOILED</org_study_id>
    <secondary_id>2010-021018-49</secondary_id>
    <nct_id>NCT01146821</nct_id>
  </id_info>
  <brief_title>Fish OIL Optimal dosE Determination Study</brief_title>
  <acronym>FOILED</acronym>
  <official_title>Multi-centre, Open-label, Phase II Clinical Trial for Determination of the Optimal Dose of Fish Oil in Patients With Severe Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Carl Gustav Carus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Giessen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Clinical Evaluation Research Unit at Kingston General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>GWT-TUD GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Carl Gustav Carus</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this trial is to determine the safety and efficacy of IV fish oil
      doses of 0.20 g/kg and 0.50 g/kg, compared to a control group, in critically ill patients
      with severe sepsis by examining organ function, blood safety and biochemical parameters,
      markers of systemic inflammation and innate immunological parameters
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: The overall objective is to determine the effect of IV fish oil on 28-day
      mortality of critically ill patients with severe sepsis. However, prior to such a large
      trial, we need to determine the optimal dose of IV fish oils in this population. Therefore,
      the primary objective of this proposal (FOILED) is to determine the safety and efficacy of IV
      fish oil doses of 0.20 g/kg and 0.50 g/kg, compared to a control group, in critically ill
      patients with severe sepsis by examining organ function, blood safety and biochemical
      parameters, markers of systemic inflammation and innate immunological parameters.

      Study Design: This is a multi-centre, open-label, phase I dose ranging clinical trial with
      prospective controls.

      Setting: 2 tertiary care ICUs in Germany (Universitätsklinikum Carl Gustav Carus, Dresden and
      University Hospital Giessen and Marburg, Giessen).

      Patients: Mechanically ventilated adult patients (&gt;18 years old) admitted to ICU with
      clinical evidence of sepsis, sepsis associated organ dysfunction, and high expression of
      inflammatory cytokines.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low enrollment/ expiration of the grant
  </why_stopped>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">April 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in SOFA score</measure>
    <time_frame>Day 1-10</time_frame>
    <description>As the primary goal of this study is to establish the safety of high doses of IV fish oils, our primary outcomes will be change in SOFA score (organ function) and biochemical parameters of safety (i.e. blood lipid levels, coagulation parameters, bleeding episodes, standard biochemistry).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Markers of systemic inflammation</measure>
    <time_frame>Day 1-10</time_frame>
    <description>Our secondary outcomes include markers of systemic inflammation [pro-calcitonin [PCT], C-reactive protein [CRP], interleukin-1 [IL-6] and IL-10) and markers of innate immunity [such as lipopolysaccharide [LPS] ex-vivo stimulation of tumor necrosis factor-alpha [TNF-α]].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical outcomes</measure>
    <time_frame>Day 1-28</time_frame>
    <description>In addition, we plan to collect clinical outcomes such as ICU and hospital length of stay, number of infections, length of ventilation, and ICU, 28-day, and hospital mortality rate</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">7</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Standard care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care + 0.20gm/kg fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard care + 0.20gm/kg fish oil</description>
  </arm_group>
  <arm_group>
    <arm_group_label>standard care + 0.50 gm/kg fish oil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>standard care + 0.50 gm/kg fish oil</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>0.20 gm/kg fish oil</intervention_name>
    <description>Group 2: 7 patients will receive 0.20gm/kg of ideal body weight [IBW] fish oil in addition to standard care</description>
    <arm_group_label>standard care + 0.20gm/kg fish oil</arm_group_label>
    <other_name>Omegaven</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>0.50 gm/kg fish oil</intervention_name>
    <description>Group 3: 7 patients will receive 0.50 gm/kg of ideal body weight [IBW] fish oil in addition to standard care.</description>
    <arm_group_label>standard care + 0.50 gm/kg fish oil</arm_group_label>
    <other_name>Omegaven</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult ICU patients

          -  Requiring invasive or non-invasive ventilation

          -  Clinical evidence of sepsis

          -  Presence of one or more organ failures

        Exclusion Criteria:

          -  &gt;24 hours from admission to ICU to time of consent

          -  Low level of inflammatory cytokine (IL-6(qualitative assay &lt;100 pg/ml)

          -  lack of commitment to full aggressive care (anticipated withholding or withdrawing
             treatments in the first week)

          -  Immunocompromised (post-organ transplantation, HIV, neutropenic [&lt;1000 PMN], steroids
             &gt;20 mgs/day for 6 months).

          -  Chronic non-invasive ventilation (except if they become mechanically ventilated)

          -  Platelet count of &lt; 30 GPt/L

          -  Pregnant patients. Urine/blood tests for pregnancy will be done on all women of
             childbearing age by each site as part of standard of ICU practice.

          -  Previous enrollment in this study

          -  Enrollment in other ICU intervention study

          -  Allergy to fish or fish oil (shellfish allergy not an exclusion criterion)

          -  Has already received enteral or IV omega-3 fatty acids during this hospitalization and
             current ICU admission.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Axel R. Heller, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Dresden, Germany</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Daren Heyland, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kingston General Hospital, Canada</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rupinder Dhaliwal, RD</last_name>
    <role>Study Director</role>
    <affiliation>Kingston General Hospital, Canada</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>D-01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Giessen and Marburg</name>
      <address>
        <city>Giessen</city>
        <zip>D-35392</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <reference>
    <citation>Pradelli L, Mayer K, Muscaritoli M, Heller AR. n-3 fatty acid-enriched parenteral nutrition regimens in elective surgical and ICU patients: a meta-analysis. Crit Care. 2012 Oct 4;16(5):R184. doi: 10.1186/cc11668. Erratum in: Crit Care. 2012;17(1):405.</citation>
    <PMID>23036226</PMID>
  </reference>
  <reference>
    <citation>Heller AR, Rössler S, Litz RJ, Stehr SN, Heller SC, Koch R, Koch T. Omega-3 fatty acids improve the diagnosis-related clinical outcome. Crit Care Med. 2006 Apr;34(4):972-9.</citation>
    <PMID>16484909</PMID>
  </reference>
  <reference>
    <citation>Heller AR, Rössel T, Gottschlich B, Tiebel O, Menschikowski M, Litz RJ, Zimmermann T, Koch T. Omega-3 fatty acids improve liver and pancreas function in postoperative cancer patients. Int J Cancer. 2004 Sep 10;111(4):611-6.</citation>
    <PMID>15239141</PMID>
  </reference>
  <reference>
    <citation>Heller AR, Fischer S, Rössel T, Geiger S, Siegert G, Ragaller M, Zimmermann T, Koch T. Impact of n-3 fatty acid supplemented parenteral nutrition on haemostasis patterns after major abdominal surgery. Br J Nutr. 2002 Jan;87 Suppl 1:S95-101.</citation>
    <PMID>11895160</PMID>
  </reference>
  <reference>
    <citation>Mayer K, Fegbeutel C, Hattar K, Sibelius U, Krämer HJ, Heuer KU, Temmesfeld-Wollbrück B, Gokorsch S, Grimminger F, Seeger W. Omega-3 vs. omega-6 lipid emulsions exert differential influence on neutrophils in septic shock patients: impact on plasma fatty acids and lipid mediator generation. Intensive Care Med. 2003 Sep;29(9):1472-81. Epub 2003 Jul 25.</citation>
    <PMID>12897994</PMID>
  </reference>
  <reference>
    <citation>Manzanares W, Dhaliwal R, Jurewitsch B, Stapleton RD, Jeejeebhoy KN, Heyland DK. Parenteral fish oil lipid emulsions in the critically ill: a systematic review and meta-analysis. JPEN J Parenter Enteral Nutr. 2014 Jan;38(1):20-8. doi: 10.1177/0148607113486006. Epub 2013 Apr 22. Review.</citation>
    <PMID>23609773</PMID>
  </reference>
  <reference>
    <citation>Pradelli L, Eandi M, Povero M, Mayer K, Muscaritoli M, Heller AR, Fries-Schaffner E. Cost-effectiveness of omega-3 fatty acid supplements in parenteral nutrition therapy in hospitals: a discrete event simulation model. Clin Nutr. 2014 Oct;33(5):785-92. doi: 10.1016/j.clnu.2013.11.016. Epub 2013 Dec 4.</citation>
    <PMID>24345520</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2010</study_first_submitted>
  <study_first_submitted_qc>June 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <last_update_submitted>April 17, 2017</last_update_submitted>
  <last_update_submitted_qc>April 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Hospital Carl Gustav Carus</investigator_affiliation>
    <investigator_full_name>Axel R. Heller</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

